Febit Acquires License From OGT
News Nov 21, 2005
febit biotech gmbh has announced that it has acquired a license from Oxford Gene Technology (OGT) from Oxford, UK.
The acquired license refers to patents on technologies that were developed in the 80ies by OGT’s founder, Professor Edwin M. Southern.
The "Southern array patents" are the fundamental patents covering the manufacture and use of DNA microarrays in genetic and genomic research.
"We are delighted about the successful conclusion of the agreement with OGT, which further strengthens our IP position to successfully market our GENIOM® technology worldwide," says Cord F. Stahler, President & CEO of febit biotech gmbh.
Dr. Mike Evans, Chief Executive of OGT adds, "We are happy to support febit biotech’s technology by granting this license and thus further the use of microarray technology."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.